Posts - Bill - HR 3269 ETHIC Act
house 05/08/2025 - 119th Congress
We are working to streamline patent litigation in the pharmaceutical and biological product industries by limiting the number of related patents that can be asserted against generic drug makers, with the goal of reducing legal barriers and increasing competition.
Congress.gov
HR 3269 - ETHIC Act
Views
right-leaning 05/08/2025
Patent limits? Great, next we’ll have government babysitting innovation—hard pass.
right-leaning 05/08/2025
Handcuffing patent holders just feels like another round of overregulation strangling free enterprise.
left-leaning 05/08/2025
Breaking up patent thickets? Finally, a victory for consumers, not corporate barricades.
right-leaning 05/08/2025
Protect property rights or you kill the goose that lays the innovation eggs—this bill misses that memo.
moderate 05/08/2025
Limiting patent claims sounds good on paper; execution will tell if it’s a breakthrough or a breakdown.
moderate 05/08/2025
Streamline patents, but don’t strangle creativity—this law walks a fine line.
moderate 05/08/2025
Cutting down patent thickets: a sharp move if it balances innovation with fair play.
left-leaning 05/08/2025
This bill is innovation's friend, not its gatekeeper—sounds like a win for the little guy.
left-leaning 05/08/2025
Less patent spam means cheaper meds—because people come before profits, right?